RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TMRC/Arafura vs Ucore/Materion As far as I am aware the Research Agreement and moneys paid related to it for work that was fulfilled is separate from the Option to Purchase Agreement unless I am mistaken. This then means that the $2.5 MM paid in advance for work not completed would be assignable to the Option to Purchase amount i would think unless that is considered as it was intended as part of the Joint Operating agreement thereby giving Ucore license to IBCs MRT technology. The money's paid for the PGM plant I don't believe would be assignable to the OTP since it was work that was done. Monies paid for the OTP agreement and extension would not be assignable to the OTP itself.
Have to be careful not to assign moneys paid to multiple entities where each had their own price.
The other factors that could impact the amount Ucore would pay for IBC are 1) IBCs valuation at the time of the purchase, 2) less any debt IBC may owe although that may be factored into the valuation, 3) less damages that Ucore may be awarded due to IBC's actions (PRs), 4) Ucore's legal and court fees if Ucore is successful in their legal actions.
I don't see where My69z's post that was shared outlines the specifics to identify something different to what I have stated.
Intrigued to see what anyone can show to identify where I am miscalculating or mistating anything. I am hoping you can.